James A. Reiffel

At the Columbia University Irving Medical Center/New York Presbyterian Hospital, Dr. Reiffel has been actively involved in teaching, research, and clinical practice. He has regularly instructed medical students, postgraduate house staff, fellows, and other faculty at the CUIMC campus and has had an active practice in consultative clinical cardiology and cardiac arrhythmic disorders, including atrial fibrillation. He has taught and continues to teach  nationally and internationally. In addition, Dr. Reiffel has been a member of the Scientific Advisory Committee of the Clinical Research Resource at the Irving Institute for Clinical and Translational Research at CUMC.

At CUIMC, Dr. Reiffel has been a faculty member of the Clinical Electrophysiology Laboratory and is s/p Director of that laboratory and the Clinical Electrophysiology fellowship program, as well as having been Co-Director of the Electrocardography Laboratory. In addition, Dr. Reiffel has served as Medical Director of the ECG Core Laboratory of the world renowned Cardiac Research Foundation.

Among his other professional activities, Dr. Reiffel is a Fellow of the American College of Physicians, the American College of Cardiology, the American Heart Association, and the Heart Rhythm Society; a member of the European Society of Cardiology, the Cardiac Safety Research consortium, AF-Screen, and of the Vascular Biology Working Group; and is a diplomate of NASPExAM. Additionally, Dr. Reiffel has been and continues to serve as a peer reviewer for multiple professional journals in medicine and in cardiology, and on the editorial board of some.

Since 1974, Dr. Reiffel has been actively engaged in the management of cardiac arrhythmic disorders. Beyond his prior patient care activities at CUIMC, Dr. Reiffel has been and continues to be involved in developmental/research studies of electrophysiological techniques, antiarrhythmic pharmaceuticals and devices, anticoagulant therapy for atrial fibrillation, and multiple major multicenter trials including, among others, CAPS, MDPIT, ESVEM, MUSTT, AVID, AFFIRM, AFFECTS, OM-8, ADONIS, ATHENA, RE-LY, HARMONY, HEARTLINE, CABANA and ORBIT-AF. Additionally, Dr. Reiffel has over 500 publications related to cardiac dysrhythmias; has been an invited lecturer at many hundreds of programs and institutions world-wide; and has served as a co-author of the antiarrhythmic drug section of the ABIM Clinical Cardiac Electrophysiology Self-Assessment Program (EPSAP) and of the cardiac arrhythmia section of the ACC self-assessment program for cardiology.

Dr. Reiffel’s current research interests include the optimum management of patients with atrial fibrillation and flutter, the development of new antiarrhythmic and anticoagulant pharmaceuticals, and the use of insertable cardiac monitors for improved detection of arrhythmias.


Education & Experience

Medical School & Residency

New York Presbyterian Hospital - Columbia Campus

Fellowship, Cardiovascular Disease

New York Presbyterian Hospital - Columbia Campus

Residency, Internal Medicine

New York Presbyterian Hospital - Columbia Campus

Internship, Transitional Year

Columbia University College of Physicians & Surgeons

Medical School

Certifications & Licensure

American Board of Internal Medicine

Certified in Cardiovascular Disease

American Board of Internal Medicine

Certified in Internal Medicine

NY State Medical License

FL State Medical License

Awards, Honors & Recognitions

Super Doc

ACC Fellow, AHA Fellow, HRS Fellow, ACP Fellow.

Cardiology Fellowship teaching award and Ewig clinical scholar.

Publications – Partial List

  • Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation.Dalgaard, F., North, R., Pieper, K., Fonarow, G. C., Kowey, P. R., Gersh, B. J., Mahaffey, K. W., Pokorney, S., Steinberg, B. A., Naccarrelli, G., Allen, L. A., Reiffel, J. A., Ezekowitz, M., Singer, D. E., Chan, P. S., Peterson, E. D., Piccini, J. P.
  • Rhythm monitoring strategies in patients at high risk for atrial fibrillation and stroke: A comparative analysis from the REVEAL AF study.Reiffel, J. A., Verma, A., Kowey, P. R., Halperin, J. L., Gersh, B. J., Elkind, M. S., Ziegler, P. D., Kaplon, R. E., Sherfesee, L., Wachter, R.
  • Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation.Freeman, J. V., Shrader, P., Pieper, K. S., Allen, L. A., Chan, P. S., Fonarow, G. C., Gersh, B. J., Kowey, P. R., Mahaffey, K. W., Naccarelli, G., Reiffel, J. A., Singer, D. E., Go, A. S., Hylek, E. M., Steinberg, B. A., Peterson, E. D., Piccini, J. P.
  • Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation.Pokorney, S. D., Holmes, D. N., Shrader, P., Thomas, L., Fonarow, G. C., Mahaffey, K. W., Gersh, B. J., Kowey, P. R., Naccarelli, G. V., Freeman, J. V., Singer, D. E., Washam, J. B., Peterson, E. D., Piccini, J. P., Reiffel, J. A.
  • Searching for Atrial Fibrillation Poststroke: A White Paper of the AF-SCREEN International Collaboration.Schnabel, R. B., Haeusler, K. G., Healey, J. S., Freedman, B., Boriani, G., Brachmann, J., Brandes, A., Bustamante, A., Casadei, B., Crijns, H. J., Doehner, W., Engström, G., Fauchier, L., Friberg, L., Gladstone, D. J., Glotzer, T. V., Goto, S., Hankey, G. J., Harbison, J. A., Hobbs, F. D., Johnson, L. S., Kamel, H., Kirchhof, P., Korompoki, E., Krieger, D. W., Lip, G. Y., Løchen, M., Mairesse, G. H., Montaner, J., Neubeck, L., Ntaios, G., Piccini, J. P., Potpara, T. S., Quinn, T. J., Reiffel, J. A., Ribeiro, A. L., Rienstra, M., Rosenqvist, M., Sakis, T., Sinner, M. F., Svendsen, J. H., Van Gelder, I. C., Wachter, R., Wijeratne, T., Yan, B.
  • Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation.Loring, Z., Shrader, P., Allen, L. A., Blanco, R., Chan, P. S., Ezekowitz, M. D., Fonarow, G. C., Freeman, J. V., Gersh, B. J., Mahaffey, K. W., Naccarelli, G. V., Pieper, K., Reiffel, J. A., Singer, D. E., Steinberg, B. A., Thomas, L. E., Peterson, E. D., Piccini, J. P.
  • Propensity Score Matching: The 'Devil is in the Details' Where More May Be Hidden than You Know.Reiffel, J. A.
  • Biomarkers and their relationship to atrial fibrillation: mechanisms, prognosis and management.Reiffel, J. A.
  • The Interaction Among Atrial Thromboembolism, Atrial Fibrillation, and Atrial Cardiomyopathy.Reiffel, J. A.
  • Changes in Management Following Detection of Previously Unknown Atrial Fibrillation by an Insertable Cardiac Monitor (from the REVEAL AF Study).Verma, A., Wachter, R., Kowey, P. R., Halperin, J. L., Gersh, B. J., Elkind, M. S., Kaplon, R. E., Ziegler, P. D., Sherfesee, L., Reiffel, J. A.
  • Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.Pokorney, S. D., Holmes, D. N., Thomas, L., Fonarow, G. C., Kowey, P. R., Reiffel, J. A., Singer, D. E., Freeman, J. V., Gersh, B. J., Mahaffey, K. W., Hylek, E. M., Naccarelli, G. V., Ezekowitz, M. D., Piccini, J. P., Peterson, E. D.
  • Stroke Rate Variation and Anticoagulation Benefit in Atrial Fibrillation.Reiffel, J. A.
  • Propensity-Score Matching: Optimal, Adequate, or Incomplete?Reiffel, J. A.
  • Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II.Inohara, T., Shrader, P., Pieper, K., Blanco, R. G., Allen, L. A., Fonarow, G. C., Gersh, B. J., Go, A. S., Ezekowitz, M. D., Kowey, P. R., Reiffel, J. A., Naccarelli, G. V., Chan, P. S., Mahaffey, K. W., Singer, D. E., Freeman, J. V., Steinberg, B. A., Peterson, E. D., Piccini, J. P.
  • Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score.Holmes, D. N.,Piccini, J. P.,Allen, L. A.,Fonarow, G. C.,Gersh, B. J.,Kowey, P. R.,O'Brien, E. C.,Reiffel, J. A.,Naccarelli, G. V.,Ezekowitz, M. D.,Chan, P. S.,Singer, D. E.,Spertus, J. A.,Peterson, E. D.,Thomas, L.
  • Reader's Comments: Beyond Atrial Fibrillation Patterns as Contributors to Risk of Thromboembolism.Reiffel, J. A.
  • Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.Packer, D. L., Mark, D. B., Robb, R. A., Monahan, K. H., Bahnson, T. D., Poole, J. E., Noseworthy, P. A., Rosenberg, Y. D., Jeffries, N., Mitchell, L. B., Flaker, G. C., Pokushalov, E., Romanov, A., Bunch, T. J., Noelker, G., Ardashev, A., Revishvili, A., Wilber, D. J., Cappato, R., Kuck, K., Hindricks, G., Davies, D. W., Kowey, P. R., Naccarelli, G. V., Reiffel, J. A., Piccini, J. P., Silverstein, A. P., Al-Khalidi, H. R., Lee, K. L.
  • Mass Screening for Atrial Fibrillation: The Hype, The Methods, and The Application.Reiffel, J. A.
  • Apples will never be oranges, but when you go fishing you may get a bite.Reiffel, J. A.
  • Complexities in the Atrial Fibrillation-Stroke Relationship: Improving Comprehension of Temporal Discordance, Magnitude Synergism, and Subclinical Atrial Fibrillation -- Three Sources of Consternation for Physicians Who Care for Patients with Atrial Fibrillation.Reiffel, J. A.
  • Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II.Essien, U. R., Holmes, D. N., Jackson, L. R., Fonarow, G. C., Mahaffey, K. W., Reiffel, J. A., Steinberg, B. A., Allen, L. A., Chan, P. S., Freeman, J. V., Blanco, R. G., Pieper, K. S., Piccini, J. P., Peterson, E. D., Singer, D. E.
  • Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF.Washam, J. B., Holmes, D. N., Thomas, L. E., Pokorney, S. D., Hylek, E. M., Fonarow, G. C., Mahaffey, K. W., Gersh, B. J., Kowey, P. R., Ansell, J. E., Go, A. S., Reiffel, J. A., Freeman, J. V., Singer, D. E., Naccarelli, G., Blanco, R., Peterson, E. D., Piccini, J. P.
  • B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation.Inohara, T.,Kim, S.,Pieper, K.,Blanco, R. G.,Allen, L. A.,Fonarow, G. C.,Gersh, B. J.,Ezekowitz, M. D.,Kowey, P. R.,Reiffel, J. A.,Naccarelli, G. V.,Chan, P. S.,Mahaffey, K. W.,Singer, D. E.,Freeman, J. V.,Steinberg, B. A.,Peterson, E. D.,Piccini, J. P.
  • Embolic and Other Adverse Outcomes in Symptomatic Versus Asymptomatic Patients With Atrial Fibrillation (from the ORBIT-AF Registry).Thind, M., Holmes, D. N., Badri, M., Pieper, K. S., Singh, A., Blanco, R. G., Steinberg, B. A., Fonarow, G. C., Gersh, B. J., Mahaffey, K. W., Peterson, E. D., Reiffel, J. A., Piccini, J. P., Kowey, P. R.
  • Letter by Reiffel Regarding Article, "Unique ECG During Sinus Rhythm in a Patient With A Postmyocardial Infarction-Sustained Ventricular Tachycardia".Reiffel, J. A.
  • Letter by Reiffel Regarding Article, "Treatment of Subclinical Atrial Fibrillation: Does One Plus One Always Equal Two?"Reiffel, J. A.
  • Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation.Durheim, M. T., Holmes, D. N., Blanco, R. G., Allen, L. A., Chan, P. S., Freeman, J. V., Fonarow, G. C., Go, A. S., Hylek, E. M., Mahaffey, K. W., Pokorney, S. D., Reiffel, J. A., Singer, D. E., Peterson, E. D., Piccini, J. P.
  • Back to the Future-New Data Confirms Old Data.Reiffel, J. A.
  • Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation.O'Brien, E. C., Holmes, D. N., Thomas, L. E., Fonarow, G. C., Allen, L. A., Gersh, B. J., Kowey, P. R., Singer, D. E., Ezekowitz, M. D., Naccarelli, G. V., Ansell, J. E., Chan, P. S., Mahaffey, K. W., Go, A. S., Freeman, J. V., Reiffel, J. A., Peterson, E. D., Piccini, J. P., Hylek, E. M.
  • Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II).Steinberg, B. A., Shrader, P., Pieper, K. S., Thomas, L., Allen, L. A., Ansell, J., Chan, P. S., Ezekowitz, M. D., Fonarow, G. C., Freeman, J. V., Gersh, B. J., Kowey, P. R., Mahaffey, K. W., Naccarelli, G. V., Reiffel, J. A., Singer, D. E., Peterson, E. D., Piccini, J. P.
  • Optimum Risk Assessment for Stroke in Atrial Fibrillation: Should We Hold the Status Quo or Consider Magnitude Synergism and Left Atrial Appendage Anatomy?Reiffel, J. A.
  • An Incomplete Story.Reiffel, J. A.
  • Time to Revisit the Time in the Therapeutic Range.Reiffel, J. A.
  • International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries.Steinberg, B. A., Gao, H., Shrader, P., Pieper, K. S., Thomas, L., Camm, A. J., Ezekowitz, M. D., Fonarow, G. C., Gersh, B. J., Goldhaber, S. Z., Haas, S., Hacke, W., Kowey, P. R., Ansell, J., Mahaffey, K. W., Naccarelli, G. V., Reiffel, J. A., Turpie, A. G., Verheugt, F. W., Piccini, J. P., Kakkar, A. K., Peterson, E. D., Fox, K. A.
  • Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes: A Multicenter Registry Study.Inohara, T., Shrader, P., Pieper, K. S., Blanco, R. G., Thomas, L., Singer, D. E., Freeman, J. V., Allen, L. A., Fonarow, G. C., Gersh, B. J., Ezekowitz, M. D., Kowey, P. R., Reiffel, J. A., Naccarelli, G. V., Chan, P. S., Steinberg, B. A., Peterson, E. D., Piccini, J. P.
  • The R-Wave Sign as a Predictor of Ventricular Tachyarrhythmias in Brugada Syndrome: The Criteria Need Verification and Clarification.Reiffel, J. A.
  • Pills Never Work in the Bottle.Reiffel, J. A.
  • Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population: The REVEAL AF Study.Reiffel, J. A., Verma, A., Kowey, P. R., Halperin, J. L., Gersh, B. J., Wachter, R., Pouliot, E., Ziegler, P. D.
  • Selective Reporting: Silent Atrial Fibrillation and Cryptogenic Strokes.Reiffel, J. A.
  • To the Editor- Minimal QT, not just maximal, may underlie TdP risk in women.Reiffel, J. A.
  • Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry.Steinberg, B. A., Shrader, P., Thomas, L., Ansell, J., Fonarow, G. C., Gersh, B. J., Kowey, P. R., Mahaffey, K. W., Naccarelli, G. V., Reiffel, J. A., Singer, D. E., Peterson, E. D., Piccini, J. P.
  • Patient factors associated with quality of life in atrial fibrillation.Randolph, T. C., Simon, D. N., Thomas, L., Allen, L. A., Fonarow, G. C., Gersh, B. J., Kowey, P. R., Reiffel, J. A., Naccarelli, G. V., Chan, P. S., Spertus, J. A., Peterson, E. D., Piccini, J. P.
  • Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men: Two-Year Results From the ORBIT-AF Registry.Piccini, J. P., Simon, D. N., Steinberg, B. A., Thomas, L., Allen, L. A., Fonarow, G. C., Gersh, B., Hylek, E., Kowey, P. R., Reiffel, J. A., Naccarelli, G. V., Chan, P. S., Spertus, J. A., Peterson, E. D.
  • NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank.Reiffel, J. A., Weitz, J. I., Reilly, P. A., Kaminskas, E., Sarich, T., Sager, P. T., Seltzer, J.
  • Ibutilide as a Torsade de Pointes Stress Test.Reiffel, J. A.
  • If it were only that simple.Reiffel, J. A.
  • Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT-AF Registry.Jackson, L. R., Kim, S. H., Piccini, J. P., Gersh, B. J., Naccarelli, G. V., Reiffel, J. A., Freeman, J. V., Thomas, L., Chang, P., Fonarow, G. C., Go, A. S., Mahaffey, K. W., Peterson, E. D., Kowey, P. R.
  • Does the FDA Owe Us an Explanation?Reiffel, J. A.
  • Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF).Steinberg, B. A., Kim, S., Thomas, L., Fonarow, G. C., Gersh, B. J., Holmqvist, F., Hylek, E. M., Kowey, P. R., Mahaffey, K. W., Naccarelli, G. V., Reiffel, J. A., Chang, P., Peterson, E. D., Piccini, J. P.
  • The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism.Reiffel, J. A., Camm, A. J., Belardinelli, L., Zeng, D., Karwatowska-Prokopczuk, E., Olmsted, A., Zareba, W., Rosero, S., Kowey, P. R.
  • Heart rate is associated with progression of atrial fibrillation, independent of rhythm.Holmqvist, F., Kim, S., Steinberg, B. A., Reiffel, J. A., Mahaffey, K. W., Gersh, B. J., Fonarow, G. C., Naccarelli, G. V., Chang, P., Freeman, J. V., Kowey, P. R., Thomas, L., Peterson, E. D., Piccini, J. P.
  • Are we at the goal line with the novel oral anticoagulants and have we reached the end of the line for dronedarone and vernakalant--or is there more to come?Reiffel, J. A.
  • Editorial: advances in the therapy of atrial fibrillation: incrementally progressive but not without missteps.Reiffel, J. A.
  • Novel oral anticoagulants.Reiffel, J. A.
  • Atrial fibrillation and stroke: epidemiology.Reiffel, J. A.
  • New versus traditional approaches to oral anticoagulation in patients with atrial fibrillation.Reiffel, J. A.
  • Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference.Kirchhof, P., Breithardt, G., Aliot, E., Khatib, S. A., Apostolakis, S., Auricchio, A., Bailleul, C., Bax, J. J., Benninger, G., Blomstrom-Lundqvist, C., Boersma, L., Boriani, G., Brandes, A., Brown, H., Brueckmann, M., Calkins, H., Casadei, B., Clemens, A., Crijns, H. J., Derwand, R., Dobrev, D., Ezekowitz, M. D., Fetsch, T., Gerth, A., Gillis, A. M., Gulizia, M., Hack, G., Haegeli, L. M., Hatem, S. N., Häusler, K. G., Heidbuechel, H., Hernandez-Brichis, J., Jais, P., Kappenberger, L., Kautzner, J., Kim, S., Kuck, K., Lane, D. A., Leute, A., Lewalter, T., Meyer, R., Mont, L., Moses, G., Mueller, M., Münzel, F., Näbauer, M., Nielsen, J. C., Oeff, M., Oto, A., Pieske, B., Pisters, R., Potpara, T. S., Rasmussen, L., Ravens, U., Reiffel, J. A., Richard-Lordereau, I., Schaefer, H., Schotten, U., Stegink, W., Stein, K. M., Steinbeck, G., Szumowski, L., Tavazzi, L., Themistoclakis, S., Thomitzek, K., Van Gelder, I. C., von Stritzky, B., Vincent, A., Werring, D. J., Willems, S., Lip, G. Y., Camm, A. J.
  • Cross-trial comparisons: a source of confusion, use, or both in the management of patients with atrial fibrillation?Iyer, V., Wang, D. Y., Reiffel, J. A.
  • Relationship between ST-segment recovery and clinical outcomes after primary percutaneous coronary intervention: the HORIZONS-AMI ECG substudy report.Farkouh, M. E., Reiffel, J. A., Dressler, O., Nikolsky, E., Parise, H., Cristea, E., Baran, D. A., Dizon, J., Merab, J. P., Lansky, A. J., Mehran, R., Stone, G. W.
  • Comparative effectiveness of warfarin and new anticoagulants.Reiffel, J. A.
  • Dronedarone: Where Does it Fit in the AF Therapeutic Armamentarium?Reiffel, J. A.
  • Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.Steinberg, B. A., Holmes, D. N., Ezekowitz, M. D., Fonarow, G. C., Kowey, P. R., Mahaffey, K. W., Naccarelli, G. V., Reiffel, J. A., Chang, P., Peterson, E. D., Piccini, J. P.
  • Correlating perceived arrhythmia symptoms and quality of life in an older population with heart failure: a prospective, single centre, urban clinic study.Hickey, K. T., Reiffel, J. A., Sciacca, R. R., Whang, W., Biviano, A. B., Baumeister, M., Castillo, C., Talathothi, J., Garan, H.
  • Dabigatran: comparison to warfarin, pathway to approval, and practical guidelines for use.Iyer, V., Singh, H. S., Reiffel, J. A.
  • The Concept of "Burden" in Atrial Fibrillation.Rosner, G. F., Reiffel, J. A., Hickey, K.
  • Letter by Reiffel regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".Reiffel, J. A.
  • An important indirect drug interaction between dronedarone and warfarin that may be extrapolated to other drugs that can alter gastrointestinal function.Reiffel, J. A.
  • Appropriate cardiac cath lab activation: optimizing electrocardiogram interpretation and clinical decision-making for acute ST-elevation myocardial infarction.Rokos, I. C., French, W. J., Mattu, A., Nichol, G., Farkouh, M. E., Reiffel, J. A., Stone, G. W.
  • Atrial fibrillation: what have recent trials taught us regarding pharmacologic management of rate and rhythm control?Reiffel, J. A.
  • The Power of One: a Highly Detailed, Log-Based, Case Example that Clearly Demonstrates the Effective Use of Ranolazine for the Control of Progressive Atrial Fibrillationn.Reiffel, J. A.
  • The Utility of Ambulatory Electrocardiographic Monitoring for Detecting Silent Arrhythmias and Clarifying Symptom Mechanism in an Urban Elderly Population with Heart Failure and Hypertension: Clinical Implications.Hickey KT, Reiffel J, Sciacca RR, Whang W, Biviano A, Baumeister M, Castillo C, Talathothi J, Garan H
  • Cardioversion for atrial fibrillation: treatment options and advances.Reiffel, J. A.
  • Dronedarone For Atrial Fibrillation: Unbridled Enthusiasm Or Just Another Small Step Forward?Reiffel, J. A.
  • Safety of bisphosphonates in the treatment of osteoporosis.Recker, R. R., Lewiecki, E. M., Miller, P. D., Reiffel, J. A.
  • QT Prolongation Following Ectopic Beats: Initial Data Regarding The Upper Limit Of Normal With Possible Implications For Antiarrhythmic Therapy And Concealed (Unexpressed) Long QT.Reiffel, A. J., Reiffel, J. A.
  • Letter by Reiffel regarding article, "Acute pharmacological conversion of atrial fibrillation to sinus rhythm".Reiffel, J. A.
  • The Anticoagulated Atrial Fibrillation Patient Who Requires "Curative" Therapy for Prostate Carcinoma: a Bleeding Conundrum.Reiffel, J. A.
  • Demystifying the rate versus rhythm conundrum: new perspectives on recent trials and future treatment options. Introduction.Reiffel, J. A.
  • Device therapies in the post-myocardial infarction patient with left ventricular dysfunction.Kadish, A. H., Reiffel, J. A., Naccarelli, G. V., DiMarco, J. P.
  • GIANT Flutter Waves in ECG Lead V1: a Marker of Pulmonary Hypertension.Reiffel, J. A.
  • An Improved QT Correction Method for use in Atrial Fibrillation and a Comparison with the Assessment of QT in Sinus Rhythm.Saluja, D., Guyotte, J. A., Reiffel, J. A.
  • Rate Versus Rhythm Control Pharmacotherapy For Atrial Fibrillation: Where are We in 2008?Reiffel, J. A.
  • Adjunctive therapy for recurrent ventricular tachycardia in patients with implantable cardioverter defibrillators.Reiffel, J. A.
  • Antiarrhythmic effects of omega-3 fatty acids.Reiffel, J. A., McDonald, A.
  • Antiarrhythmic drug therapy for atrial fibrillation: are the guidelines guiding clinical practice?Reiffel, J. A., Naccarelli, G. V.
  • Practical algorithms for pharmacologic management of the post myocardial infarction patient.Reiffel, J. A.
  • Drug and drug-device therapy in heart failure patients in the post-COMET and SCD-HeFT era.Reiffel, J. A.
  • The potential for changing prescribing patterns from warfarin to oral direct thrombin inhibitors: clinical scenarios.Reiffel, J. A.
  • Formulation substitution: a frequently overlooked variable in cardiovascular drug management.Reiffel, J. A.
  • Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation?Reiffel, J. A.
  • Change in the retrograde atrial activation sequence following radiofrequency modification of the atrioventricular node: implications for the electrophysiologic circuit of a variant of atrioventricular nodal reentrant tachycardia.Dizon J, Reiffel J, Kassotis J, Woollett I, Garan H
  • Microcomplex--a new incomplete heart block pattern.Reiffel, J. A., Cook, J. R.
  • Cardiology patient page. The implantable cardioverter-defibrillator: patient perspective.Reiffel, J. A., Dizon, J.
  • Is it rational, reasonable or excessive, and consistently applied? One view of the increasing FDA emphasis on safety first for the release and use of antiarrhythmic drugs for supraventricular arrhythmias.Reiffel JA
  • Importance of QT interval determination and renal function assessment during antiarrhythmic drug therapy.Reiffel JA, Appel G
  • Issues in the use of generic antiarrhythmic drugs.Reiffel JA
  • Time dependent changes in duration of ventricular repolarization after AV node ablation: insights into the possible mechanism of postprocedural sudden death.Dizon J, Blitzer M, Rubin D, Coromilas J, Costeas C, Kassotis J, Reiffel J
  • Effects of aging and gender on QT dispersion in an overtly healthy population.Kassotis J, Costeas C, Bedi AK, Tolat A, Reiffel J
  • The actions of ibutilide and class Ic drugs on the slow sodium channel: new insights regarding individual pharmacologic effects elucidated through combination therapies.Reiffel JA, Blitzer M
  • Formulation substitution and other pharmacokinetic variability: underappreciated variables affecting antiarrhythmic efficacy and safety in clinical practice.Reiffel JA
  • Drug choices in the treatment of atrial fibrillation.Reiffel JA
  • Generic antiarrhythmics are not therapeutically equivalent for the treatment of tachyarrhythmias.Reiffel JA, Kowey PR
  • Inpatient versus outpatient antiarrhythmic drug initiation: safety and cost-effectiveness issues.Reiffel JA
  • The importance of considering trial design when interpreting clinical trial results.Reiffel JA
  • Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial.Exner DV, Reiffel JA, Epstein AE, Ledingham R, Reiter MJ, Yao Q, Duff HJ, Follmann D, Schron E, Greene HL, Carlson MD, Brodsky MA, Akiyama T, Baessler C, Anderson JL
  • Predictability of response rates, efficacy, risks, and intolerance with sotalol when used for sustained ventricular arrhythmias.Reiffel JA
  • Selecting an antiarrhythmic agent for atrial fibrillation should be a patient-specific, data-driven decision.Reiffel JA
  • Importance of beta blockade in the therapy of serious ventricular arrhythmias.Reiter MJ, Reiffel JA
  • Antiarrhythmic drugs and devices for the management of ventricular tachyarrhythmia in ischemic heart disease.Reiffel JA, Reiter MJ, Blitzer M
  • Double-wave reentry in orthodromic atrioventricular reciprocating tachycardia: paradoxical shortening of the tachycardia cycle length with development of ipsilateral bundle branch block.Coromilas J, Kassotis J, Dizon J, Reiffel J, Costeas C, Lipka L
  • Rhythm management in atrial fibrillation--with a primary emphasis on pharmacologic therapy: Part 3.Kassotis J, Costeas C, Blitzer M, Reiffel JA
  • Impact of structural heart disease on the selection of class III antiarrhythmics for the prevention of atrial fibrillation and flutter.Reiffel JA
  • Rhythm management in atrial fibrillation--with a primary emphasis on pharmacological therapy: Part 2.Costeas C, Kassotis J, Blitzer M, Reiffel JA
  • Rhythm management in atrial fibrillation--with a primary emphasis on pharmacological therapy: Part 1.Blitzer M, Costeas C, Kassotis J, Reiffel JA
  • Prolonging survival by reducing arrhythmic death: pharmacologic therapy of ventricular tachycardia and fibrillation.Reiffel JA
  • Sotalol for ventricular tachyarrhythmias: beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure. ESVEM Investigators. Electrophysiologic Study Versus Electrocardiographic Monitoring.Reiffel JA, Hahn E, Hartz V, Reiter MJ
  • Effects of the ventricular activation sequence on the JT interval.Banker J, Dizon J, Reiffel J
  • Reproducibility of drug efficacy predictions by Holter monitoring in the electrophysiologic study versus electrocardiographic monitoring (ESVEM) trial. ESVEM Investigators.Reiter MJ, Karagounis LA, Mann DE, Reiffel JA, Hahn E, Hartz V
  • Implications of the Electrophysiologic Study versus Electrocardiographic Monitoring trial for controlling ventricular tachycardia and fibrillation.Reiffel JA
  • Exploration of the precision of classifying sudden cardiac death. Implications for the interpretation of clinical trials.Pratt CM, Greenway PS, Schoenfeld MH, Hibben ML, Reiffel JA
  • A summary and assessment of the findings and conclusions of the ESVEM trial.Mason JW, Marcus FI, Bigger JT, Lazzara R, Reiffel JA, Reiter MJ, Mann D
  • Influence of Holter monitor and electrophysiologic study methods and efficacy criteria on the outcome of patients with ventricular tachycardia and ventricular fibrillation in the ESVEM trial.Reiffel JA, Reiter MJ, Freedman RA, Mann D, Huang SK, Hahn E, Hartz V, Mason J
  • Desired mechanisms of drugs for ventricular arrhythmia: class III antiarrhythmic agents.Lipka LJ, Dizon JM, Reiffel JA
  • How do physicians determine when to perform an "on-drug" electrophysiology study for efficacy determination in patients with sustained ventricular tachyarrhythmias: a previously unaddressed variable that may affect efficacy rates.Reiffel JA, Banker J
  • Structural heart disease: its importance in association with antiarrhythmic drug therapy.Reiffel JA, Correia J
  • "In the absence of structural heart disease...." What is it, and why does it matter in antiarrhythmic drug therapy?Reiffel JA, Correia J
  • Left atrial appendage function and thrombus formation in atrial fibrillation-flutter: a transesophageal echocardiographic study.Santiago D, Warshofsky M, Li Mandri G, Di Tullio M, Coromilas J, Reiffel J, Homma S
  • Electrophysiological testing of sinus node function: diagnostic and prognostic application-including updated information from sinus node electrograms.Reiffel JA, Kuehnert MJ
  • A consensus report on antiarrhythmic drug use.Reiffel JA, Estes NA, Waldo AL, Prystowsky EN, DiBianco R
  • Evolutionary paths in arrhythmia management: influences of substrate, studies, and seismology.Reiffel JA, Correia J
  • Improved rate control in atrial fibrillation.Reiffel JA
  • Evidence suggesting time-dependent recovery of excitability in the in vivo human sinus node.Reiffel JA, Cook JA, Meissner MD
  • Optimum duration of transtelephonic ECG monitoring when used for transient symptomatic event detection.Reiffel JA, Schulhof E, Joseph B, Severance E, Wyndus P, McNamara A
  • Physician attitudes toward the use of type IC antiarrhythmics after the Cardiac Arrhythmia Suppression Trial (CAST).Reiffel JA, Cook JR
  • The duration of the sinus node depolarization on transvenous sinus node electrograms can identify sinus node dysfunction and can suggest its severity.Reiffel JA, Zimmerman G
  • Efficacy, safety, and tolerance of d-sotalol in patients with refractory supraventricular tachyarrhythmias.Sahar DI, Reiffel JA, Bigger JT, Squatrito A, Kidwell GA
  • Relation of baseline characteristics to suppression of ventricular arrhythmias during placebo and active antiarrhythmic therapy in patients after myocardial infarction.Anderson JL, Hallstrom AP, Griffith LS, Ledingham RB, Reiffel JA, Yusuf S, Barker AH, Fowles RE, Young JB
  • Phase analysis of gated blood pool scintigraphic images to localize bypass tracts in Wolff-Parkinson-White syndrome.Johnson LL, Seldin DW, Yeh HL, Spotnitz HM, Reiffel JA
  • Sensitivity, specificity, and reproducibility of programmed ventricular stimulation.Bigger JT, Reiffel JA, Livelli FD, Wang PJ
  • Usefulness of atrioventricular nodal Wenckebach periodicity in predicting sinus nodal entrance block during atrial pacing.Wang P, Reiffel JA, Zimmerman J, Livelli F, Gliklich J, Ferrick K, Bigger JT, Noethling P
  • Transcatheter ablation: safety and convenience modifications.Reiffel JA
  • Electrophysiologic testing in patients with recurrent syncope: are results predicted by prior ambulatory monitoring?Reiffel JA, Wang P, Bower R, Bigger JT, Livelli F, Ferrick K, Gliklich J, Zimmerman J
  • Sinus node echoes and concealed concealed conduction: additional sinus node phenomena confirmed in man by direct sinus node electrography.Reiffel JA, Bigger JT, Ferrick K, Livelli FD, Gliklich J, Wang P, Bosner R
  • Drug-device interactions: clinical considerations.Reiffel JA, Coromilas J, Zimmerman JM, Spotnitz HM
  • Electrophysiologic studies of the sinus node and atria.Reiffel JA, Ferrick K, Zimmerman J, Bigger JT
  • Further evidence for decremental conduction in the sinoatrial junction.Reiffel JA
  • Prognosis after recovery from acute myocardial infarction.Bigger JT, Coromilas J, Weld FM, Reiffel JA, Rolnitzky LM
  • Current status of direct recordings of the sinus node electrogram in man.Reiffel JA, Bigger JT
  • Indirectly estimated sinoatrial conduction time by the atrial premature stimulus technique: patterns of error and the degree of associated inaccuracy as assessed by direct sinus node electrography.Reiffel JA, Gang E, Livelli F, Gliklich J, Bigger JT
  • Holter versus electrophysiologic studies in the management of malignant ventricular arrhythmias.Bigger JT, Reiffel JA
  • Sinus node recovery times following the spontaneous termination of supraventricular tachycardia and following atrial overdrive pacing: a comparison.Gang ES, Reiffel JA, Livelli FD, Bigger JT
  • Sinus node recovery time related to paced cycle length in normals and patients with sinoatrial dysfunction.Reiffel JA, Gang E, Bigger JT, Livelli F, Rolnitzky L, Cramer M
  • Response to programmed ventricular stimulation: sensitivity, specificity and relation to heart disease.Livelli FD, Bigger JT, Reiffel JA, Gang ES, Patton JN, Noethling PM, Rolnitzky LM, Gliklich JI
  • Four-contact glove probe method for rapid recording of cardiac electrograms during surgery.Spotnitz HM, Gliklich JI, Ross S, Reiffel JA, Malm JR, Bigger JT, Hoffman BF
  • Electrophysiologic effects of procainamide on sinus function in patients with and without sinus node disease.Goldberg D, Reiffel JA, Davis JC, Gang E, Livelli F, Bigger JT
  • Quinidine-digoxin interaction: time course and pharmacokinetics.Leahey EB, Bigger JT, Butler VP, Reiffel JA, O'Connell GC, Scaffidi LE, Rottman JN
  • Clinical and electrophysiologic characteristics of sinoatrial entrance block evaluated by direct sinus node electrography: prevalence, relation to antegrade sinoatrial conduction time, and relevance to sinus node disease.Reiffel JA, Gang E, Livelli F, Gliklich J, Bigger JT
  • Optic neuritis and heart block in Kearns-Sayre syndrome.Davis JC, Reiffel JA, Behrens M, Rowland L, Mascitelli R, Seplowitz A
  • Sinus node dysfunction caused by methyldopa and digoxin.Davis JC, Reiffel JA, Bigger JT
  • The human sinus node electrogram: a transvenous catheter technique and a comparison of directly measured and indirectly estimated sinoatrial conduction time in adults.Reiffel JA, Gang E, Gliklich J, Weiss MB, Davis JC, Patton JN, Bigger JT
  • The effect of quinidine and other oral antiarrhythmic drugs on serum digoxin. A prospective study.Leahey EB, Reiffel JA, Giardina EG, Bigger JT
  • Does DC cardioversion affect isoenzyme recognition of myocardial infarction?Reiffel JA, McCarthy DM, Leahey EB
  • Enhanced cardiac effect of digoxin during quinidine treatment.Leahey EB, Reiffel JA, Heissenbuttel RH, Drusin RE, Lovejoy WP, Bigger JT
  • Effects of digoxin on sinus nodal function before and after vagal blockade in patients with sinus nodal dysfunction: a clue to the mechanisms of the action of digitalis on the sinus node.Reiffel JA, Bigger JT, Cramer M
  • A previously unrecognized drug interaction between quinidine and digoxin.Reiffel JA, Leahey EB, Drusin RE, Heissenbuttel RH, Lovejoy W, Bigger JT
  • Sick sinus syndrome.Bigger JT, Reiffel JA
  • Pure anterior conduction delay: a variant "fascicular" defect.Reiffel JA, Bigger JT
  • Interaction between quinidine and digoxin.Leahey EB, Reiffel JA, Drusin RE, Heissenbuttel RH, Lovejoy WP, Bigger JT
  • Direct current cardioversion. Effect on creatine kinase, lactic dehydrogenase and myocardial isoenzymes.Reiffel JA, Gambino SR, McCarthy DM, Leahey EB
  • Ability of Holter electrocardiographic recording and atrial stimulation to detect sinus nodal dysfunction in symptomatic and asymptomatic patients with sinus bradycardia.Reiffel JA, Bigger JT, Cramer M, Reid DS
  • Augmentation of auscultatory and echocardiographic mitral valve prolapse by atrial premature depolarizations.Reiffel JA, Green WM, King DL
  • Case studies: Simultaneous intermittent intraatrial and intraventricular conduction defects mimicking trifascicular conduction delay.Reiffel JA, Antman EM, Casella AJ, Drusin R
  • Letter: Ventricular tachycardia.Reiffel JA
  • "Paradoxical" prolongation of sinus nodal recovery time after atropine in the sick sinus syndrome.Reiffel JA, Bigger JT, Giardina EG
  • Diagnosis of acute myocardial infarction. Relative efficiency of serum enzyme and isoenzyme measurements.Galen RS, Reiffel JA, Gambino R
  • The relationship between sinoatrial conduction time and sinus cycle length during spontaneous sinus arrhythmia in adults.Reiffel JA, Bigger JT, Konstam MA
  • Enzymes in infarction.Galen RS, Reiffel JA, Gambino SR


Last updated, August 19, 2020